Clinical trial
Effect of Roflumilast on Exacerbation Rate in Patients With Chronic Obstructive…
NCT00297102 · AstraZeneca, Industry · Completed
Key facts
| NCT number | NCT00297102 |
|---|---|
| Title | Effect of Roflumilast on Exacerbation Rate in Patients With Chronic Obstructive Pulmonary Disease (COPD): The AURA Study (BY217/M2-124) |
| Official title | Effect of Roflumilast on Exacerbation Rate in Patients With COPD. The AURA Study |
| Lead sponsor | AstraZeneca, Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Chronic Obstructive Pulmonary Disease (COPD) |
| Intervention type | Drug |
| Interventions | Roflumilast, Placebo |
| Enrollment | 1,523 |
| Start date | Feb 1, 2006 |
| Primary completion | Jul 1, 2008 |
| Completion | Sep 1, 2008 |
| First posted | Feb 28, 2006 |
| Last update posted | Jan 16, 2017 |
| Countries | Australia, Austria, Brazil, France, Germany, Hungary, New Zealand, Romania, Russia, United Kingdom, United States |
At a glance
- 100–999 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: